Ketoconazole and other potent antimycotic azoles exhibit pronounced activity against Trypanosoma cruzi, Plasmodium berghei and Entamoeba histolytica in vivo.
D000562:Amebiasis / Q000188:drug therapy*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D014355:Chagas Disease / Q000188:drug therapy*; D004748:Entamoeba histolytica / Q000187:drug effects; D004749:Entamoebiasis / Q000188:drug therapy*; D007654:Ketoconazole / Q000494:pharmacology / Q000627:therapeutic use*; D008288:Malaria / Q000188:drug therapy*; D051379:Mice; D009593:Nitroimidazoles / Q000627:therapeutic use; D010962:Plasmodium berghei / Q000187:drug effects; D014349:Trypanosoma cruzi / Q000187:drug effects
D000935:Antifungal Agents; D009593:Nitroimidazoles; D007654:Ketoconazole; C009999:benzonidazole